Nephrectomy for metastatic renal-cell cancer [4] (multiple letters)

New England Journal of Medicine

Volumn 346, Issue 14, 2002, Pages 1095-1096

  Bolger, Graeme ^a   Sitki Copur, M ^a   Ledakis, Peter ^a   Norvell, Max ^a   Polo, Jorge L ^a   Schwartz, Jonathan D ^a   Flanigan, Robert C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT;

CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; HUMAN; KIDNEY CANCER; LETTER; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SIDE EFFECT; KIDNEY CARCINOMA; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; NOTE; PATHOLOGY; SURVIVAL; PSYCHOLOGICAL ASPECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; NEPHRECTOMY; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; QUALITY OF LIFE;

EID: 0037018587     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200204043461417     Document Type: Letter

References (0)